Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

BioPoly® Partial Resurfacing Knee Implant IDE

A legfontosabb adatok

Ki végzi
BioPoly LLC
Hol
Chesterfield, Fort Wayne, Indianapolis, Louisville, Redwood City és Rochester (Egyesült Államok)Mind a 6 helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
152 fő, tervezett
Kezdés
2025. márc. 17.
Várható befejezés
2028. dec.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • BioPoly
  • surgical standard of care (SSOC)
A regiszteradat frissítve
2026. november 12.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with knee pain from a cartilage damage spot on the end of the thigh bone (distal femur) who can have knee surgery. They get either the BioPoly implant or standard surgery (microfracture or debridement).

Életkor
30 to 65 years
Nem
All sexes
A betegség stádiuma
Cartilage lesion on the femoral condyle or trochlear facet, ICRS grade 2, 3 or 4. Lesion no larger than 3.1 cm2, less than 4mm deep, surrounded by normal or nearly normal cartilage. KOOS quality of life score ≤ 60.
Korábbi kezelés
Non-surgical treatment (such as NSAID, injections, physical therapy) must have failed after at least 2 months, or earlier knee surgery (such as debridement, marrow stimulation, high tibial osteotomy) must have failed at least 12 months ago. People whose ACI, OATS or Allograft treatment failed cannot join.

A részvétel fő kizáró okai

  • Body mass index (BMI) ≥ 35
  • Advanced osteoarthritis in the knee (Kellgren-Lawrence Grade 4), autoimmune arthritis or gout
  • Osteoporosis, osteopenia or other bone disease, or weak bone under the lesion
  • Knee misalignment over 5 degrees, unrepaired ligament instability, or total meniscus removal
  • Pregnant or planning pregnancy, uncontrolled diabetes, or allergy to titanium alloy, UHMWPE or hyaluronic acid

A regiszter feltételei, szó szerint

Mind a 32 feltétel megnézéseKevesebb

Ki vehet részt

  • Patient is between 30 and 65 years of age25
  • KOOS quality of life score ≤ 60
  • In the opinion of the Investigator, the patient has the understanding and willingness to comply with all study requirements including the Post-Operative rehabilitation and follow-up protocol
  • Patient has cartilage lesion that has failed non-surgical conservative therapy (e,g, anti-inflammatory (NSAID), viscosupplementation, steroid injection, physical therapy, or activity modification) after at least 2 months of beginning the therapy or failed surgical conservative therapy (e.g. debridement/lavage, marrow stimulation, or alignment high tibial osteotomy) that was performed at least 12 months ago in the index knee and is a candidate for surgical intervention
  • Patient has cartilage lesion located in the femoral condyle or trochlear facet
  • Patient has lesion(s) classified as ICRS grade 2, 3 or 4
  • Patient's lesion size may not exceed 3.1 cm2 and must be circumscribed by a 1.5 cm or 2.0 cm diameter circle, or 1.5 cm (M-L) by 2.4 cm (A-P) oval of normal or nearly normal (ICRS grade 0 or 1) cartilage, with an overall depth less than 4mm from the articulating surface
  • Patient has subchondral bone quality that is non-osteoporotic and is sufficient to support the implant. The quality of bone will be assessed by the surgeon intraoperatively with a surgical instrument such as an awl

Ki nem vehet részt

  • Contralateral knee is known to have symptomatic cartilage, meniscal, or ligamentous lesions, generalized osteoarthritis, or requires surgery
  • Patient has a cartilage lesion that is being treated with a non-surgical conservative therapy (e,g, anti-inflammatory (NSAID), viscosupplementation, steroid injection, physical therapy, or activity modification) and it has been < 2 months since beginning treatment or the patient's cartilage lesion has failed surgical therapy (e.g. debridement/lavage, marrow stimulation, alignment (high tibial osteotomy)) in the index knee and it has been < 12 months since the surgical treatment
  • Patient is participating in other studies and/or receiving any other simultaneous therapy in index knee
  • Patient has an uncorrected tear of the meniscus of the index knee. (Partial meniscectomy that retains >50% of the meniscus is allowed prior to or concurrently with the cartilage treatment procedure. Meniscus suture repair is allowed prior to or concurrently with the cartilage treatment procedure if >50% of the functional meniscus remains.)
  • More than one implant is required to accommodate defect in the index knee
  • Patient has inadequate bone stock (e.g., cysts, osteoporosis) underlying the lesion site as determined intra-operatively by the investigator; As determined by the investigator through use of an awl or a similar instrument to determine if the bone quality is insufficient to support the BioPoly device; If the cause of inadequate bone stock is due to cysts or to the boney portion of an osteochondral lesion being excessive, then the investigator may opt to fix the implant with cement rather than exclude the patient for inadequate bone stock
  • Patient has autoimmune arthritis, as diagnosed by Investigator
  • Patient has uncorrected ligamentous instability (good joint stability in the index joint with a Grade 1 Lachman or less, no pivot shift for ACL insufficiency and no posterior translation of more than grade 1; no deficits in flexion or extension of > 10 degrees compared to contralateral knee) in the index knee
  • Patient currently reports or has a documented history of uncontrolled diabetes
  • Patient currently has any condition, therapy, or medication known to impair bone healing
  • Patient has had an active systemic infection or joint infection in index knee over the last 12 months
  • Patient has an allergy to titanium alloy (Ti-6Al-4V), ultrahigh molecular weight polyethylene (UHMWPE), or hyaluronan/ hyaluronic acid (HA)
  • Patients with osteoporosis, osteopenia, Paget's disease, osteomalacia or any other metabolic bone disease; a. Osteoporosis is defined as Simple Calculated Osteoporosis Risk Estimation (SCORE) above 6 and DXA T-score < -2.5 or QCT T-score < 80mg/cubic cm. History of a fragility fracture requires that a DXA scan or QCT scan is completed
  • Patient has body mass index (BMI) ≥ 35
  • Patient has advanced degenerative osteoarthritis in index knee (Kellgren-Lawrence Grade 4 and/or diagnosed intraoperatively)
  • Patient has gout, by Investigator diagnosis or patient-reported history within last 12 months
  • Patient has a cartilage lesion that is being treated that has failed ACI, OATS or Allograft treatment
  • Patient has malalignment of the index knee (>5 degrees weight bearing varus or valgus)
  • Patient has bipolar articular cartilage involvement (or kissing lesions) of the ipsilateral compartment (i.e. greater than ICRS Grade 2 on the opposing articular surface) in the index knee
  • Patient has undergone a total meniscectomy of index knee
  • Patient has undergone patellofemoral arthroplasty of the index knee
  • Patient is pregnant or is planning to become pregnant (for female patients only) at any point during the duration of the study
  • Patient has legal involvement or any other issue that would hinder completion of the two-year follow-up period
  • Patient has an additional cartilage lesion(s) (ICRS Grade 3 or 4) in the index knee, located on the patella, trochlea, tibia, or non-weight bearing area of index condyle that requires treatment

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 30 és 65 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Washington University OrthopedicsChesterfield, Egyesült ÁllamokContact: Susan BrandonRésztvevőt keres
  • Dupont HospitalFort Wayne, Egyesült ÁllamokContact: Ian Nelson, MD (principal investigator)Résztvevőt keres
  • OrthoIndyIndianapolis, Egyesült ÁllamokContact: Sheila Schwartz, R.Ph.No longer taking part
  • University of LouisvilleLouisville, Egyesült ÁllamokContact: Jolynn Roberts Research CoordinatorRésztvevőt keres
  • Stanford Medicine Dept of Orthopaedic SurgeryRedwood City, Egyesült ÁllamokContact: Allen SeoRésztvevőt keres
  • Mayo ClinicRochester, Egyesült ÁllamokContact: Noelle DrapeauRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this randomized controlled clinical trial is to demonstrate the safety and effectiveness of the BioPoly® Partial Resurfacing Knee Implant for the treatment of cartilage defects of the distal femur in adult patients with knee pain and symptoms who are candidates for surgical intervention of the knee compared to outcomes for the control group.

A teljes eredeti leírásKevesebb

The primary effectiveness endpoint is Month 24 composite clinical success (CCS) defined by:

* no secondary surgical intervention (SSI) and * an improvement from baseline in the Knee injury and Osteoarthritis Outcome Score (KOOS) total score (scaled 0 to 100) of at least 10 points.

Researchers will compare the CCS for the investigational device group to a control group receiving the standard of care, either microfracture or debridement).

Subjects randomized to the investigational group will receive the BioPoly Knee device and those randomized to the control group will receive the current standard of care, either microfracture or debridement.

A vizsgálat 2 csoportja

  • InvestigationalMár használt kezelés, összehasonlításként

    BioPoly Knee device

    Kezelés: BioPoly

  • ControlMár használt kezelés, összehasonlításként

    Surgical Standard of Care Group: either Microfracture or debridement procedure

    Kezelés: surgical standard of care (SSOC)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Pivotal, Prospective, Randomized, Controlled, Multicenter Clinical Trial of BioPoly® Partial Resurfacing Knee Implant for Treatment of Focal Cartilage Lesions of the Distal Femur
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT06915363: ki vehet részt
A regiszteradat frissítve
2026. november 12.